Parties involved in valsartan cancer lawsuits have put forward 28 potential early test cases to serve as bellwether trials to represent at least 600 claims the recalled hypertension drugs contained high levels of NDMA.…
A federal judge has cleared the way for valsartan NDMA lawsuits to proceed against manufacturers of the tainted hypertension drugs.…
A new study questions whether hypertension drugs have a negative impact on patients with COVID-19 infections.…
Two former district judges have been appointed as Special Masters in valsartan litigation, with hopes they will bring the parties to a settlement agreement.…
Valsartan proceedings will continue throughout 2021, with the first trials unlikely to be held before 2022.…
Parties in valsartan litigation have dueling arguments over the validity of the litigation as defendants seek to have the Master Complaint dismissed.…
The FDA has issued new guidance on how industry should work to avoid further contamination by NDMA and similar carcinogens.…
The FDA warns that two crucial tuberculosis antibiotic drugs may contain high levels of nitrosamine impurities which may increase cancer risks, but will not recall the drugs due to the risk of a shortage.…
A new study finds that valsartan and similar drugs do not increase the risk of poor outcomes from COVID-19.…
New study questions whether hypertension drugs increase severity of COVID-19.…
